Event JSON
{
"id": "084c92a4e54e06d1d3a9cfbe757e6056014092c254866c1f86b1d90b7978610e",
"pubkey": "052466631c6c0aed84171f83ef3c95cb81848d4dcdc1d1ee9dfdf75b850c1cb4",
"created_at": 1721835419,
"kind": 1,
"tags": [
[
"r",
"https://www.theguardian.com/global-development/article/2024/jul/23/hiv-aids-prevention-vaccine-lenacapavir-sunlenca-pharmaceuticals-gilead-generic-licensing"
],
[
"monero",
"75qFDfm3GAyXrsT6CmZA31haHdubPNwoG2h1tyEQ41juFAjtABdEvfH7ai1bvAvHsmcYz1aPncRgWVUxKGdVCsyEPoLW4rL",
"1.0"
]
],
"content": "\"Lenacapavir, sold as Sunlenca by US pharmaceutical giant Gilead, currently costs $42,250 for the first year. The company is being urged to make it available at a thousand times less than that price worldwide.\"\n\nhttps://www.theguardian.com/global-development/article/2024/jul/23/hiv-aids-prevention-vaccine-lenacapavir-sunlenca-pharmaceuticals-gilead-generic-licensing",
"sig": "cc200e61186b71f5845d2be8f5c86dac68157e95e7e21d3928e6f60b1f77e479fa02caca0c349ed93176f8fbc9dc96238d0b10041a3571093bbb77c2eeb26a31"
}